FDA Approves Nypozi (filgrastim-txid), a Biosimilar to Neupogen

July 1, 2024

FDA approves Nypozi (filgrastim-txid), a biosimilar to Neupogen, indicated to decrease the incidence of infection in patients with non-myeloid malignancies.

Highlighted Terms

NEUPOGEN Neupogen Tanvex BioPharma, Inc.U.S. Food and Drug Administration filgrastim-txid Nypozi

Related News

drugs.com

FDA Approves Nypozi (filgrastim-txid), a Biosimilar to Neupogen

FDA approves Nypozi (filgrastim-txid), a biosimilar to Neupogen, indicated to decrease the incidence of infection in patients with non-myeloid malignancies.